Two three-dimensional pillared metal–OLSALAZINE (cas 15722-48-2) complexes based on infinite rod-shaped secondary building units
-
Add time:09/09/2019 Source:sciencedirect.com
The first two three-dimensional (3D) pillared metal–olsalazine complexes, namely [Co(osa)0.5(bim)0.5(H2O)] (1) and [Cd(osa)0.5(bim)0.5(H2O)] (2) (H4osa = 3,3-azo-bis(6-hydroxybenzoic acid), bim = 1,4-bis(imidazol-1-yl)butane) have been hydrothermally synthesized and further characterized by single-crystal X-ray diffraction, powder X-ray diffraction, elemental analysis, IR spectra and TG analyses. Compounds 1 and 2 are isostructural, and their frameworks are composed of infinite rod-shaped secondary building units (SBUs) that are bridged by osa ligands to form 2D layers, which are further pillared by bim ligands in the third dimension. To the best of our knowledge, it is the first time that 3D pillared-layer frameworks involving infinite rod-shaped SBUs have been obtained in the realm of metal–olsalazine complexes. The magnetic property of 1 and photoluminescence of 2 have also been investigated.
We also recommend Trading Suppliers and Manufacturers of OLSALAZINE (cas 15722-48-2). Pls Click Website Link as below: cas 15722-48-2 suppliers
Prev:Degradation kinetics of metronidazole and OLSALAZINE (cas 15722-48-2) by bacteria in ascending colon and in feces of healthy adults
Next:An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “OLSALAZINE (cas 15722-48-2)”) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Determination of mesalazine, a low bioavailability OLSALAZINE (cas 15722-48-2) metabolite in human plasma by UHPLC–MS/MS: Application to a pharmacokinetic study09/24/2019
- An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “OLSALAZINE (cas 15722-48-2)”09/10/2019
- Degradation kinetics of metronidazole and OLSALAZINE (cas 15722-48-2) by bacteria in ascending colon and in feces of healthy adults09/08/2019
- Full paperOld drug, new indication: OLSALAZINE (cas 15722-48-2) sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity09/07/2019
- Research paperEx vivo evaluation of degradation rates of metronidazole and OLSALAZINE (cas 15722-48-2) in distal ileum and in cecum: The impact of prandial state09/06/2019
- On the encapsulation of OLSALAZINE (cas 15722-48-2) by β-cyclodextrin: A DFT-based computational and spectroscopic investigations09/05/2019
- Synthesis of novel (bio) degradable linear azo polymers conjugated with OLSALAZINE (cas 15722-48-2)09/04/2019
- Enzyme and PH responsive 5-flurouracil (5-FU) loaded hydrogels based on OLSALAZINE (cas 15722-48-2) derivatives for colon-specific drug delivery09/03/2019


